114 related articles for article (PubMed ID: 10205291)
1. Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis.
Birk D; Gansauge F; Gansauge S; Schwarz A; Beger HG
Eur J Med Res; 1999 Apr; 4(4):156-60. PubMed ID: 10205291
[TBL] [Abstract][Full Text] [Related]
2. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
Lundin J; Roberts PJ; Kuusela P; Haglund C
Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
[TBL] [Abstract][Full Text] [Related]
4. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
Malaguarnera M; Cristaldi E; Cammalleri L; Colonna V; Lipari H; Capici A; Cavallaro A; Beretta M; Alessandria I; Luca S; Motta M
Arch Gerontol Geriatr; 2009; 48(2):213-7. PubMed ID: 18329114
[TBL] [Abstract][Full Text] [Related]
5. Neopterin--a potential factor for differentiation between pancreatic cancer and chronic pancreatitis.
Piecuch J; Rudzki M; Orkisz W; Swietochowska E; Wielkoszyński T; Waniczek D; Arendt J; Sosada K; Zurawiński W; Ładny JR
Hepatogastroenterology; 2008; 55(81):258-61. PubMed ID: 18507120
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
7. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
8. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
9. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis.
Pezzilli R; Billi P; Beltrandi E; Mancini R; Casadei-Maldini M; Casadei R; Greco VM; Campione O; Miglioli M
Ital J Gastroenterol; 1994 Apr; 26(3):137-40. PubMed ID: 8061340
[TBL] [Abstract][Full Text] [Related]
11. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8.
Neurauter G; Grahmann AV; Klieber M; Zeimet A; Ledochowski M; Sperner-Unterweger B; Fuchs D
Cancer Lett; 2008 Dec; 272(1):141-7. PubMed ID: 18701209
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.
Avanzas P; Arroyo-Espliguero R; Quiles J; Roy D; Kaski JC
Eur Heart J; 2005 Mar; 26(5):457-63. PubMed ID: 15684278
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
Safi F; Roscher R; Beger HG
Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
16. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.
Weinlich G; Murr C; Richardsen L; Winkler C; Fuchs D
Dermatology; 2007; 214(1):8-14. PubMed ID: 17191041
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of neopterin in patients with lichen planus.
Krasowska D; Chodorowska G; Bartosińska J; Warmińska J; Jermak A; Kur A; Kowal A; Bogaczewicz J
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):346-50. PubMed ID: 16146010
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Teknos TN; Cox C; Yoo S; Chepeha DB; Wolf GT; Bradford CR; Carey TE; Fisher SG
Head Neck; 2002 Nov; 24(11):1004-11. PubMed ID: 12410536
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
